ASH 2020 – Multiple Myeloma

APOLLO: Daratumumab + Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone in Patients with RRMM

Compared with pomalidomide and dexamethasone (Pd) alone, daratumumab + Pd reduced the risk for disease progression and death without additional safety signals for patients with RRMM who had received ≥1 prior lines of therapy, including lenalidomide and a proteasome inhibitor. Read More ›

Idecabtagene Vicleucel, a BCMA-Directed CAR T-Cell Therapy, in Patients with RRMM: CRB-401 Study Updates

ASH 2020 – Multiple Myeloma

Updated analysis of the phase 1 CRB-401 study supports a favorable clinical benefit–risk profile for the BCMA-directed CAR T-cell therapy, idecabtagene vicleucel, in RRMM at target dose levels of ≥150 × 106 CAR+ T-cells. Read More ›

CARTITUDE-1: Ciltacabtagene Autoleucel, a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy, in RRMM

ASH 2020 – Multiple Myeloma

Preliminary results from the phase 1b/2 CARTITUDE-1 study reveal early, deep, and durable responses and a safety profile consistent with prior studies with a single low-dose infusion of ciltacabtagene autoleucel in heavily pretreated patients with RRMM. Read More ›

FORTE Trial: Analysis of Survival in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma

ASH 2020 – Multiple Myeloma

In the FORTE trial, patients with NDMM who were transplant-eligible experienced significantly improved progression-free survival with carfilzomib + lenalidomide + dexamethasone (KRd) induction-ASCT-KRd consolidation versus either 12 KRd cycles or carfilzomib + cyclophosphamide + dexamethasone (KCd) induction-ASCT-KCd consolidation. Read More ›

Isatuximab + Pomalidomide and Dexamethasone in Frail Patients with RRMM: ICARIA-MM Subgroup Analysis

ASH 2020 – Multiple Myeloma

The ICARIA-MM investigators studied the effects of isatuximab + pomalidomide and dexamethasone in the subgroup of frail patients with RRMM, and results support use of the regimen among these patients. Read More ›

Minimal Residual Disease After Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

ASH 2020 – Multiple Myeloma

Interim results from a phase 2 trial exploring the response to ixazomib, lenalidomide, and dexamethasone induction followed by a single autologous stem-cell transplantation, IRd consolidation, and risk-based maintenance showed an overall response rate of 93%. Read More ›

Cobimetinib as Monotherapy and in Combination with Venetoclax with or without Atezolizumab in Patients with RRMM

ASH 2020 – Multiple Myeloma

Preliminary results from this phase 1b/2 study of cobimetinib alone or plus venetoclax, with or without atezolizumab, in patients with RRMM show manageable toxicity, moderate efficacy overall, and higher efficacy for t(11;14) patients. Read More ›

BFCR4350A, a FcRH5 x CD3 T-Cell–Engaging Bispecific Antibody, in Patients with RRMM: Preliminary Clinical Activity and Safety

ASH 2020 – Multiple Myeloma

Preliminary results from the GO39775 study show promising efficacy and manageable toxicity for BFCR4350A as monotherapy in patients with RRMM with high-risk cytogenetics, triple-class refractory disease, and/or prior exposure to anti-CD38 monoclonal antibodies, CAR T-cells, or antibody–drug conjugates. Read More ›

Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

ASH 2020 – Multiple Myeloma

The interim results from a phase 2 trial examining the response to ixazomib, lenalidomide, and dexamethasone induction in newly diagnosed, transplant-eligible patients showed an overall response rate of 93%. Read More ›

A Phase 2 Study of Isatuximab for Patients with Previously Treated AL Amyloidosis

ASH 2020 – Multiple Myeloma

Preliminary results from a phase 2 study of isatuximab in patients with amyloid light-chain (AL) amyloidosis who were previously treated showed encouraging efficacy and a good safety profile. Read More ›

ASH 2020 – Multiple Myeloma

Page 1 of 3